AstraZeneca loses Symbicort patent in Europe
Executive Summary
The European Patent Office has revoked the patent covering AstraZeneca's Symbicort (formoterol/budesonide) for treatment of asthma, the company announces Oct. 18. The company does not believe the EPO decision will have an immediate impact in the EU or any impact on the U.S. or Japanese patents...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.